While the use of human induced pluripotent stem cells (iPSCs) in regenerative medicine is a long-term goal, a growing body of studies has shown promising results in the fields of drug discovery, development, and toxicity screening. Specifically, recent technological advancement has enabled the generation of patient-specific and disease-specific human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) in vitro. In the lecture Professor Wu will discuss recent advances in this technology in the cardiovascular field.
29 August 2016 | 4:00 pm
Auditorium CharitéCrossOver (CCO), Campus Charité Mitte (Virchowweg 6, 10177 Berlin)
No registration required.